1[2]Heathcote EJ.Management of primary biliary cirrhosis:the American Association for the study of liver diseases practice guidelines.Heptology,2000,31:1005-1013.
2[3]Dalekos GN,Zachou K,Iiaskos C,et al.Autoantibodies and defined target autoantigens in autoimmune hepatitis:an overview.Eur J Intern Med,2002,13:293 -303.
1Heathcote EJ. Management of primary biliary cirrhosis. The American Association for the Study of Liver Diseases practice guidelines.Hepatology, 2000, 31: 1005-1013.
2Alvarez F, Berg PA, Bianchi FB, et al. International Autoimmune Hepatitis Group Report: review of criteria for diagnosis of autoimmane hepatitis. J Hepatol, 1999, 31: 929-938.
3Leung PS, Van de Water J, Coppel RL, et al. Molecular aspects and the pathological basis of primary biliary cirrhosis. J Autoimmun,1996, 9: 119-128.
4Metcalf JV, Mitchison HC, Palmer JM, et al. Natural history of early primary biliary cirrhosis. Lancet, 1996,348: 1399-1402.
5Thomsen BL, Sorensen TI. Analysis of the treatment effect on recurrent bleeding and death in patients with cirrhosis and esophageal varices: multistage competing-risks model compared to conventional methods. J Hepatol, 1998, 28: 107-114.
7International Autoimmune Hepatitis Group Report: Review of Criteria for Diagnosisof Autoimmune Hepatitis. J Hepatol, 1999, 31: 929-938.
8Wies I, Brunner S, Henninger J, et al. Identification of target antigen for SLA/LPautoantibodies in autoimmune hepatitis. Lancet, 2000, 355: 1510-1515.
9Lapierre P, Hajoui O, Homberg JC, et al. Formiminotransferase cyclodeaminase is anorgan-specific autoantigen recognized by sera of patients with autoimmune hepatits.Gastroenterology, 1999, 116: 643-649.
10Lohse AW, Meyer zum Buschenfelde KH, Franz B, et al. Characterization of theoverlap syndrome of primary biliary cirrhosis (PBC) and autoimmune hepatitis: evidence forit being a hepatitic form of PBC in genetically susceptible individuals. Hepatology, 1999,29: 1080-1084.
8Sobajima J,Ozaki S,Uesugi H,et al.High mobility group (HMG) non-histone chromosomal proteins HMG 1 and HMG2 are sign if icant target antigens of perinuclear anti-neutrophi cytoplasmic antibodies in autoimmune hepatitis.Gut,1999,44(6):867-873.
9Leibovitch L,George J,Levi Y,et al.Anti-actin antibodies in sera from patients with autoimmune liver diseases and patients with carcinomas by ELISA.Immunol Lett,1995,48:129-132.
10Worman HJ,Courvalin JC.Antinuclear antibodies specific for primary biliary cirrhosis.Autoimmun Rev,2003,2:211-217.
